close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,225.73 +42.57 (+3.60%)
Official Closing Price Updated: 7:00 PM EDT, Aug 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Why Eli Lilly (LLY) Stock Is Up Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiri... 
Via StockStory
News headline image
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? ↗
PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names. 
Via The Motley Fool
Topics ETFs
News headline image
PPH vs. IYH: Which Healthcare Fund Is the Better Buy? ↗
PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings. 
Via The Motley Fool
Topics ETFs
News headline image
U.S. Physical Therapy Names Nchacha Etta as Chief Financial Officer /www.snipeso ↗
Outpatient physical therapy operators regularly strengthen their executive leadership to support long-term operational scaling and strategic financial mana 
Via Talk Markets
Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup ↗
Via Chartmill
News headline image
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations. 
Via The Motley Fool
News headline image
If I Were in My 20s, I'd Buy This Unstoppable Vanguard ETF and Hold It Forever ↗
Investors can reap big rewards over the long term by betting on growth in their younger years. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Why Is Omniab Stock Rallying After Eli Lilly Deal? ↗
The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket 
Via Benzinga
News headline image
Wall Street Says the Stock Market's Return Will Crush the Long-Term Average in the Next Year ↗
The S&P 500 returned 9.5% annually over the past two decades. Wall Street expects much bigger gains in the next year. 
Via The Motley Fool
Topics Stocks
News headline image
1 of Wall Street’s Favorite Stocks on Our Watchlist and 2 We Find Risky
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
2 GLP-1 Stocks That Could Double Your Money by 2031 ↗
They are fairly risky, but their potential upside is massive. 
Via The Motley Fool
News headline image
Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient ↗
The company's peers in the pharmaceutical industry should be worried. 
Via The Motley Fool
News headline image
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) ↗
They are way more than just GLP-1 stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger ↗
The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker. 
Via The Motley Fool
News headline image
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins? ↗
Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year. 
Via The Motley Fool
Topics ETFs
News headline image
Amphastar (AMPH) Q2 2026 Earnings Call Transcript ↗
New product launches drove 5% revenue growth and margin expansion. 
Via The Motley Fool
Topics Earnings
News headline image
Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now? ↗
Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or Simplify's Actively Managed PINK? ↗
Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity ↗
The stock continues to look unstoppable. 
Via The Motley Fool
News headline image
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating? ↗
It's yet another setback for the drugmaker. 
Via The Motley Fool
News headline image
IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play? ↗
FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly (LLY) Q2 2026 Earnings Call Transcript ↗
Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised. 
Via The Motley Fool
Topics Earnings
News headline image
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities ↗
Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks. 
Via Benzinga
Topics Law Enforcement Lawsuit
News headline image
1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run ↗
It has proven to be a market-beater in more years than not. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited grow... 
Via StockStory
Topics Earnings
News headline image
Better Buy: Eli Lilly vs. Novo Nordisk ↗
Novo Nordisk is playing catch-up in the GLP-1 race. 
Via The Motley Fool
News headline image
Absci Q2 Earnings Call Highlights ↗
Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis,... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now ↗
SpaceX has attractive prospects, but the market has already factored that into its share price. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy ↗
Omada Health (NASDAQ:OMDA) highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic... 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.